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Introduction
Large cross-sectional studies have demonstrated that cardiovascular (CV) risk begins to increase in early stage chronic kidney disease (CKD) when estimated glomerular filtration rate (eGFR) levels are ~75 ml/min/1.73m 2 and that risk increases progressively as eGFR falls. 1 There is increasing evidence that adverse changes in cardiac structure and function are present early in the course of CKD; the prevalence of left ventricular (LV) hypertrophy on 2D echocardiography rises with a graded inverse relationship to eGFR 2 and sub-clinical systolic and diastolic dysfunction is detectable using tissue Doppler echocardiography. 3 It is not known however, whether diffuse interstitial fibrosis occurs in early stage CKD and if present, whether it is associated with adverse changes in LV function. We hypothesized that diffuse interstitial fibrosis measured using cardiac magnetic resonance imaging (CMR) is present in early stage CKD and is associated with myocardial dysfunction.
Methods
Patients were prospectively recruited from renal clinics at the Queen Elizabeth Hospital
Birmingham, England between 2012 and 2014. Inclusion criteria were: CKD stage 2 (eGFR 60-89 ml/min/1.73m 2 with other evidence of kidney disease: proteinuria / haematuria / structural abnormality / genetic), stage 3 (eGFR 30-59 ml/min/1.73m 2 ) and stage 4 (15-29 ml/min/1.73m 2 ) with no history or symptoms of CV disease or diabetes. Estimated GFR was measured by the 4-Variable Modification of Diet in Renal Disease formula. Subjects were compared to i) age and gender matched healthy controls recruited as part of an on-going clinical study 4 and ii) age and gender matched, treated hypertensive patients referred to a dedicated hypertension clinic. The study was approved by the National Research Ethics Service -South Birmingham (12/WM/0250) and all subjects gave informed consent.
Subjects underwent CMR (1.5T Avanto, Siemens Healthcare, Erlangen, Germany). Left and right ventricular volumes, mitral annular plane systolic excursion (MAPSE), ejection fraction (EF) and LV mass index (LVMI) were acquired in line with standard CMR protocols. Left atrial volumes (LA) were calculated using the biplane area-length method. The four-chamber and short axis steady-M A N U S C R I P T A C C E P T E D Figure 1 ). Endocardial borders were drawn manually in the enddiastolic frame for each image. The CMR-FT software automatically propagated the contour and followed its through the cardiac cycle. Global longitudinal peak systolic strain (GLS), peak systolic strain rate (GLSR) and early diastolic strain rate (GLSRe) were derived.
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Quantitative parametric T1 images were generated using Argus software (Siemens®) with manual contouring to define a region of interest (ROI) in the LV septum at basal and mid myocardial levels. Global native (non-contrast) myocardial T1 time (ms) was calculated from the averaged T1 times in the LV septum basal and mid ventricular ROIs before contrast administration and global ECV after contrast using validated formulae 6, 7 :
Hct refers to the haematocrit recorded on a venous blood sample at the time of scan, ∆R1 = 1/T1 time post contrast -1/T1 time pre contrast. Lambda (λ) refers to (1/ T1 myocardium post contrast -1/T1 myocardium pre-contrast)/ (1/ T1 blood post contrast -1/ T1 blood pre-contrast).
ROIs were drawn to exclude any areas of LGE consistent with previously undiagnosed infarction and RV insertion point LGE, consistent with previous published methodology ( Figure 2 ). 6 Myocardial intracellular volume (ICV) was also calculated as; 1-ECV providing a measure of cell volume which is important when interpreting the composition of the myocardium with LV hypertrophy. 6 All data were analysed by a single experienced observer (NCE). 
Results
In total, 129 subjects were studied across the three groups without significant differences in age and gender. The leading aetiologies of renal disease were primary glomerular nephropathy (37%), adult polycystic kidney disease (APKD, 21%), quiescent vasculitis (SLE, Wegeners granulomatosis, 16%). Patient characteristics are presented in Table 1 .
There were no differences in LV volumes or LVEF between groups (Table 2) . LA volumes were increased in CKD compared to controls and hypertensive subjects. Only 2/43 (5%) patients with CKD and 2/43 (5%) patients with hypertension had a LVMI above normal limits for LV hypertrophy.
Patients with CKD had reduced GLS, GLSR and GLSRe compared to controls and hypertensive subjects. (Table 2) CKD was associated with higher native T1 ( Table 2 and Figure 3a ) and lower post-contrast T1 values (419 ± 52ms vs. 465 ± 50ms vs. 497 ± 37ms, p<0.01) than controls and hypertensive subjects, respectively. ECV was increased in subjects with CKD compared to controls and hypertensive subjects (Table 2 and Figure 3b ) with a clear shift of the ECV histogram to the right.
Subjects in the top quartile of ECV (>0.29) had lower ICV, LV mass, GLS and GLSR without a M A N U S C R I P T
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6 difference in LVEF or LV volumes. There were no differences in ECV between the stages of CKD or between controls and hypertensive subjects (Table 2) . Intra-observer variability of ECV data was low; intra-class correlation 0.96 (95% CI 0.88-0.986).
Thirteen patients (30%) with CKD had evidence of LGE in a non-coronary artery distribution;
6 subjects had mid-wall or epicardial LGE; 7 subjects had LGE at the RV insertion points. None of the foci of LGE were located within the ROIs drawn within the septum and therefore no area of LGE was included in calculation of native T1 times or septal ECV. There was no subendocardial LGE suggestive of previous myocardial infarction. After exclusion of CKD patients with LGE, native T1
times and ECV remained increased in CKD subjects (T1 984ms ± 40 and ECV 0.27 ± 0.03) compared with controls and hypertensive subjects vs. (T1 957ms ± 27, p<0.05, ECV 0.25 ± 0.03, p<0.05).
In univariate analysis, native myocardial T1 times were inversely associated with GLS (r = -0.22, p<0.05) and GLSR (r = -0.30, p<0.05). ECV was also associated with reduced GLS (r = -0.43, p<0.01) and GLSR (r = -0.23, p<0.05). There was no association between ECV and LVEF, LVMI, NT-proBNP or eGFR.
Discussion
This is the first study to assess diffuse interstitial fibrosis using T1 mapping CMR in patients with early CKD. Longer native T1 times correlate closely with histological quantitation of myocardial fibrosis, based on cardiac biopsy in subjects with aortic stenosis undergoing valve replacement. 8, 9 The technique is now well established and has been used to identify adverse clinical outcomes in other disease groups including diabetes 10 , valvular heart disease 9 and amyloidosis. 11 Extracellular volume expansion on CMR also correlates closely with histological quantitation of myocardial fibrosis. 8, 9, 12, 13 The assessment of ECV however, requires administration of intravenous gadolinium contrast (comparing pre-contrast T1 and post-contrast T1 values from the myocardium) whereas measurement of native myocardial T1 time allows assessment of myocardial composition without contrast. In this study, longer native myocardial T1 times in CKD subjects were consistent with the elevation in ECV and with shorter post-contrast myocardial T1 times than were observed in hypertension subjects or M A N U S C R I P T
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7 healthy controls, although the T1-sequence used is more susceptible to differences in relaxivity than newer sequences such as sh-MOLLI. 12 It is clear that T1 mapping has considerable potential in the ESRD population where concerns remain about the risk of nephrogenic systemic fibrosis with gadolinium chelates.
14 Elevation in ECV is important, since this identifies individuals at greater risk for total and cardiovascular mortality. 15 In population studies, elevation in ECV appears to be of similar but independent adverse prognostic significance to reduction in LVEF. 16 There was no evidence of a reduction in systolic function measured by LVEF in patients with CKD in this study, although both our group and others have shown previously that such a change is not common in CKD. 2, 3 Indeed, the prognostic value of EF is limited when in the normal range. 17 There were however, reductions in GLS and GLSR that carry independent, adverse prognostic significance both in CKD 18 and in other populations. 19 Both GLS and GLSR are more sensitive and perform better than LVEF in predicting major cardiac events 19 and all-cause mortality in many cardiac conditions. 20 In our study, subjects with early CKD also had evidence of impaired diastolic relaxation, reflected in reduced GLSRe and increased LA volume (a sensitive marker of increased LV end-diastolic pressure). These reductions in systolic and diastolic function are consistent with previous data in early CKD acquired using tissue Doppler echocardiography. 3 Furthermore, increased LA volume is associated with an adverse prognosis in ESRD. 21 It has been suggested that these changes in myocardial systolic and diastolic deformation are functional markers of diffuse interstitial fibrosis, although it is not possible to identify from our data whether LV dysfunction arises due to the presence of diffuse interstitial fibrosis, or whether both are consequences of damage in CKD that occur as part of the final common pathway to uremic cardiomyopathy (UC) and ultimately heart failure.
In our study, ECV was not elevated and GLS/SR were not reduced in subjects with hypertension. These findings are in contrast to a previous study which showed reduced LV systolic strain in hypertensive subjects who had uncontrolled BP (mean 161/101mmHg) and LV hypertrophy. 22 Our findings are consistent with those of Narayanan et al. who found similar myocardial strain values in hypertensive subjects and healthy controls. 23 In both our study and that of M A N U S C R I P T
8 Narayanan, mean BP was better controlled 137/82mmHg and neither study recruited patients with LV hypertrophy. The elevation in ECV in our study in early CKD compared to those with hypertension is important, suggesting that the mechanisms driving the development of diffuse interstitial fibrosis and the alteration in myocardial function are not BP dependent. Histological studies do indicate that reactive interstitial fibrosis can be found in hypertension but this is due to accumulation of type I and type III collagen fibres in advanced disease. 24 In contrast biopsies from patients with ESRD have shown severe myocyte hypertrophy, myocyte disarray and extensive interstitial fibrosis. 25 This study does not address mechanisms for the development of diffuse fibrosis in CKD but factors likely worthy of further investigation include: aldosterone 26 , the phosphaturic hormone fibroblast growth factor 23 (FGF-23) 27 and high intracellular phosphate levels which actively promote transformation of vascular smooth muscle cells. 28 There is also an association between urinary protein and sodium excretion and LV mass on CMR, independent of blood pressure which requires explanation. 29 Further work to examine associations and investigate possible mechanisms is required.
This was a cross-sectional, observational study and while we have shown associations between ECV and myocardial T1 times with markers of LV function, this does not prove any causative relationship. Longitudinal studies are needed to define whether LV dysfunction arises as a result of progressive fibrosis or not. We acknowledge the lower haematocrit levels in CKD compared to other subjects which might influence calculation of ECV. These data would not affect native myocardial T1 times and indeed are consistent with haematocrit data published in studies of ECV in both diabetics 10 and systemic sclerosis. 
